Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...

The US Food and Drug Administration (FDA) on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of ...

The US Food and Drug Administration (FDA) has approved use of the vaccine Yeztugo, manufactured by Gilead Sciences, is an anti-HIV drug.

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...

The United States Food and Drug Administration (FDA) has approved a twice-a-year drug to be used to prevent HIV.

The United States Food and Drug Administration, FDA, has approved a new long-acting injectable drug, Lenacapavir, for the ...

The Food and Drug Administration has approved a highly effective new HIV prevention medication, known as Yeztugo. In clinical ...

Gilead Sciences, Inc. GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the ...

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

Gilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...